📰 Controlled Trial News
Controlled Trial News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Controlled Trial. Real-time updates on events, politics, business and more.
May 19, 2024
Finding and treating people with undiagnosed asthma or chronic obstructive pulmonary disease (COPD) improved their health and reduced their health care visits for respiratory symptoms in the year after diagnosis, according to a world-first clinical trial published in the New England Journal of Medicine.
April 30, 2024
Ultra-processed foods have been linked with negative health outcomes but they aren't all bad. Which? nutritionist Shefalee Loth explains the facts behind the fear
April 30, 2024
/PRNewswire/ -- Olympus, a global medical technology company committed to making peoples lives healthier, safer and more fulfilling, will highlight a diverse...
March 28, 2024
Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today a milestone for its iTindtm device with its availability and greater patient access through the largest healthcare group...
February 22, 2024
Discover the truth about green powders: "Are Green Powders A Waste Of Money?" Learn how they can supplement your diet in 2024 .
December 27, 2023
The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.
December 19, 2023
Home remedies offer you herbal and natural methods to treat high blood pressure or hypertension. Follow these simple and natural remedies to lower or control high blood pressure.
December 6, 2023
These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.
November 21, 2023
/PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced grants awarded for developing innovative...
November 16, 2023
The ravulizumab group had a proteinuria reduction of 40.3% while the placebo group had a reduction of 10.9% by week 26, highlighting ravulizumab’s effectiveness in treating patients with IgA Nephropathy.